

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Cyclosporine Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Carcinogenicity, Category 1B      H350: May cause cancer.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H350 May cause cancer.

Precautionary statements : **Prevention:**

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

P201 Obtain special instructions before use.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

### Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

### Storage:

P405 Store locked up.

### Hazardous components which must be listed on the label:

Cyclosporine

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Cyclosporine	59865-13-3	Acute Tox. 4; H302 Carc. 1B; H350 Repr. 1B; H360Df STOT RE 1; H372 (Kidney, Liver, Immune system)	>= 0.1 - < 0.3

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	610640-00017	Date of first issue: 08.04.2016

---

advice.

- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause cancer.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	610640-00017	Date of first issue: 08.04.2016

---

### 5.3 Advice for firefighters

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
- 

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

- Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

- Methods for cleaning up : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe vapours.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

- Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
- Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Self-reactive substances and mixtures  
Organic peroxides  
Explosives  
Gases

### 7.3 Specific end use(s)

- Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Petrolatum	8009-03-8	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m <sup>3</sup>	IE OEL
Cyclosporine	59865-13-3	TWA	10 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9.33 mg/kg food

### 8.2 Exposure controls

#### Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

#### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to I.S. EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state : viscous liquid

Colour : colourless, to, light yellow

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	610640-00017	Date of first issue: 08.04.2016

---

Initial boiling point and boiling range : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity  
Viscosity, kinematic : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics  
Particle size : Not applicable

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	610640-00017	Date of first issue: 08.04.2016

---

### SECTION 10: Stability and reactivity

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

#### 10.4 Conditions to avoid

Conditions to avoid : None known.

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

### SECTION 11: Toxicological information

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Cyclosporine:

Acute oral toxicity : LD50 (Rat): 1,480 mg/kg  
LD50 (Mouse): 2,329 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Mouse): 107 mg/kg  
Application Route: Intravenous  
LD50 (Rat): 25.8 mg/kg  
Application Route: Intravenous



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

---

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Cyclosporine:

Remarks : No data available  
May irritate skin.

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Cyclosporine:

Remarks : No data available  
May irritate eyes.

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### Cyclosporine:

Remarks : May cause sensitisation of susceptible persons.

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Cyclosporine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster cells  
Result: negative

Test Type: sister chromatid exchange assay  
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

---

Species: Chinese hamster  
Cell type: Bone marrow  
Result: negative

Test Type: Chromosomal aberration  
Species: Mouse  
Result: negative

### **Carcinogenicity**

May cause cancer.

#### **Components:**

##### **Cyclosporine:**

Species : Mouse  
Application Route : Oral  
Exposure time : 78 weeks  
LOAEL : 4 mg/kg body weight  
Result : positive  
Target Organs : Liver, lymphatic system

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
LOAEL : 0.5 mg/kg body weight  
Result : positive  
Target Organs : Pancreas

Species : Humans  
Result : May cause cancer.  
Target Organs : Immune system, Skin  
Remarks : Information taken from reference works and the literature.

Carcinogenicity - Assessment : May cause cancer.

### **Reproductive toxicity**

Not classified based on available information.

#### **Components:**

##### **Cyclosporine:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity F1: LOAEL: 15 mg/kg body weight  
Result: No effects on fertility, Effect on reproduction capacity

Test Type: Fertility  
Species: Rat, males  
Application Route: Subcutaneous  
Fertility: LOAEL: 10 mg/kg body weight  
Result: Reduced fertility

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

---

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 30 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced foetal weight, foetal mortality, Retardations, Teratogenic effects

Test Type: Embryo-foetal development  
Species: Rabbit  
Developmental Toxicity: LOAEL: 100 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced foetal weight, foetal mortality, Retardations, Teratogenic effects

Test Type: Development  
Species: Rabbit  
Application Route: Subcutaneous  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Target Organs: Kidney  
Result: Visceral malformations

Test Type: Development  
Species: Rat  
Application Route: Intravenous  
Developmental Toxicity: LOAEL: 12 mg/kg body weight  
Target Organs: Heart  
Result: Visceral malformations

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Components:

#### Cyclosporine:

Target Organs : Kidney, Liver, Immune system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Cyclosporine:

Species : Rat  
NOAEL : 14 mg/kg  
LOAEL : 45 mg/kg

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

---

Application Route : Oral  
Exposure time : 90 Days  
Target Organs : Kidney, Liver, Immune system  
Symptoms : hair loss

Species : Monkey  
NOAEL : 20 mg/kg  
LOAEL : 60 mg/kg  
Application Route : Oral  
Exposure time : 90 Days  
Target Organs : Immune system  
Symptoms : Gastrointestinal disturbance, Liver disorders, Kidney disorders

Species : Dog  
LOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 12 Months  
Target Organs : Immune system  
Symptoms : Changes in the blood count, Kidney disorders, Skin disorders, hair loss

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

##### **Cyclosporine:**

Inhalation : Remarks: May cause irritation of respiratory tract.  
Skin contact : Remarks: May irritate skin.  
Eye contact : Symptoms: Eye irritation, eye pain  
Ingestion : Symptoms: Kidney disorders, Tremors, hypertension, blood effects, Gastrointestinal disturbance

---

## SECTION 12: Ecological information

### 12.1 Toxicity

No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	610640-00017	Date of first issue: 08.04.2016

---

### 12.2 Persistence and degradability

No data available

### 12.3 Bioaccumulative potential

No data available

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.  
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.  
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

---

**IATA** : Not regulated as a dangerous good

### 14.2 UN proper shipping name

**ADN** : Not regulated as a dangerous good

**ADR** : Not regulated as a dangerous good

**RID** : Not regulated as a dangerous good

**IMDG** : Not regulated as a dangerous good

**IATA** : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

**ADN** : Not regulated as a dangerous good

**ADR** : Not regulated as a dangerous good

**RID** : Not regulated as a dangerous good

**IMDG** : Not regulated as a dangerous good

**IATA** : Not regulated as a dangerous good

### 14.4 Packing group

**ADN** : Not regulated as a dangerous good

**ADR** : Not regulated as a dangerous good

**RID** : Not regulated as a dangerous good

**IMDG** : Not regulated as a dangerous good

**IATA (Cargo)** : Not regulated as a dangerous good

**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:  
Number on list 75, 3

If you intend to use this product as tattoo ink, please contact your vendor.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

---

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.  
Not applicable

### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302 : Harmful if swallowed.

H350 : May cause cancer.

H360Df : May damage the unborn child. Suspected of damaging fertili-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version 3.1      Revision Date: 30.09.2023      SDS Number: 610640-00017      Date of last issue: 04.04.2023  
Date of first issue: 08.04.2016

H372 : ty.  
Causes damage to organs through prolonged or repeated exposure.

### Full text of other abbreviations

Acute Tox. : Acute toxicity  
Carc. : Carcinogenicity  
Repr. : Reproductive toxicity  
STOT RE : Specific target organ toxicity - repeated exposure  
IE OEL : List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2  
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

**Classification procedure:**



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
3.1	30.09.2023	610640-00017	Date of first issue: 08.04.2016

---

Carc. 1B

H350

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN